Literature DB >> 24055113

Actionable, pathogenic incidental findings in 1,000 participants' exomes.

Michael O Dorschner1, Laura M Amendola, Emily H Turner, Peggy D Robertson, Brian H Shirts, Carlos J Gallego, Robin L Bennett, Kelly L Jones, Mari J Tokita, James T Bennett, Jerry H Kim, Elisabeth A Rosenthal, Daniel S Kim, Holly K Tabor, Michael J Bamshad, Arno G Motulsky, C Ronald Scott, Colin C Pritchard, Tom Walsh, Wylie Burke, Wendy H Raskind, Peter Byers, Fuki M Hisama, Deborah A Nickerson, Gail P Jarvik.   

Abstract

The incorporation of genomics into medicine is stimulating interest on the return of incidental findings (IFs) from exome and genome sequencing. However, no large-scale study has yet estimated the number of expected actionable findings per individual; therefore, we classified actionable pathogenic single-nucleotide variants in 500 European- and 500 African-descent participants randomly selected from the National Heart, Lung, and Blood Institute Exome Sequencing Project. The 1,000 individuals were screened for variants in 114 genes selected by an expert panel for their association with medically actionable genetic conditions possibly undiagnosed in adults. Among the 1,000 participants, 585 instances of 239 unique variants were identified as disease causing in the Human Gene Mutation Database (HGMD). The primary literature supporting the variants' pathogenicity was reviewed. Of the identified IFs, only 16 unique autosomal-dominant variants in 17 individuals were assessed to be pathogenic or likely pathogenic, and one participant had two pathogenic variants for an autosomal-recessive disease. Furthermore, one pathogenic and four likely pathogenic variants not listed as disease causing in HGMD were identified. These data can provide an estimate of the frequency (∼3.4% for European descent and ∼1.2% for African descent) of the high-penetrance actionable pathogenic or likely pathogenic variants in adults. The 23 participants with pathogenic or likely pathogenic variants were disproportionately of European (17) versus African (6) descent. The process of classifying these variants underscores the need for a more comprehensive and diverse centralized resource to provide curated information on pathogenicity for clinical use to minimize health disparities in genomic medicine.
Copyright © 2013 The American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 24055113      PMCID: PMC3791261          DOI: 10.1016/j.ajhg.2013.08.006

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  26 in total

Review 1.  Monogenic hypercholesterolemia: new insights in pathogenesis and treatment.

Authors:  Daniel J Rader; Jonathan Cohen; Helen H Hobbs
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

2.  'Racial' differences in genetic effects for complex diseases.

Authors:  John P A Ioannidis; Evangelia E Ntzani; Thomas A Trikalinos
Journal:  Nat Genet       Date:  2004-11-14       Impact factor: 38.330

3.  Principal components analysis corrects for stratification in genome-wide association studies.

Authors:  Alkes L Price; Nick J Patterson; Robert M Plenge; Michael E Weinblatt; Nancy A Shadick; David Reich
Journal:  Nat Genet       Date:  2006-07-23       Impact factor: 38.330

4.  The future of incidental findings: should they be viewed as benefits?

Authors:  Lisa S Parker
Journal:  J Law Med Ethics       Date:  2008       Impact factor: 1.718

5.  Reporting genetic results in research studies: summary and recommendations of an NHLBI working group.

Authors:  Ebony B Bookman; Aleisha A Langehorne; John H Eckfeldt; Kathleen C Glass; Gail P Jarvik; Michael Klag; Greg Koski; Arno Motulsky; Benjamin Wilfond; Teri A Manolio; Richard R Fabsitz; Russell V Luepker
Journal:  Am J Med Genet A       Date:  2006-05-15       Impact factor: 2.802

6.  p53 compound heterozygosity in a severely affected child with Li-Fraumeni syndrome.

Authors:  S Quesnel; S Verselis; C Portwine; J Garber; M White; J Feunteun; D Malkin; F P Li
Journal:  Oncogene       Date:  1999-07-08       Impact factor: 9.867

7.  Proportionally more deleterious genetic variation in European than in African populations.

Authors:  Kirk E Lohmueller; Amit R Indap; Steffen Schmidt; Adam R Boyko; Ryan D Hernandez; Melissa J Hubisz; John J Sninsky; Thomas J White; Shamil R Sunyaev; Rasmus Nielsen; Andrew G Clark; Carlos D Bustamante
Journal:  Nature       Date:  2008-02-21       Impact factor: 49.962

8.  Compound-heterozygous Marfan syndrome.

Authors:  F S Van Dijk; B C Hamel; Y Hilhorst-Hofstee; B J M Mulder; J Timmermans; G Pals; J M Cobben
Journal:  Eur J Med Genet       Date:  2008-11-27       Impact factor: 2.708

9.  Germline mutations of the E-cadherin(CDH1) and TP53 genes, rather than of RUNX3 and HPP1, contribute to genetic predisposition in German gastric cancer patients.

Authors:  G Keller; H Vogelsang; I Becker; S Plaschke; K Ott; G Suriano; A R Mateus; R Seruca; K Biedermann; D Huntsman; C Döring; E Holinski-Feder; A Neutzling; J R Siewert; H Höfler
Journal:  J Med Genet       Date:  2004-06       Impact factor: 6.318

10.  Population structure and eigenanalysis.

Authors:  Nick Patterson; Alkes L Price; David Reich
Journal:  PLoS Genet       Date:  2006-12       Impact factor: 5.917

View more
  195 in total

1.  Consenting for molecular diagnostics.

Authors:  Robert Klitzman
Journal:  Clin Chem       Date:  2014-11-12       Impact factor: 8.327

Review 2.  Human genotype-phenotype databases: aims, challenges and opportunities.

Authors:  Anthony J Brookes; Peter N Robinson
Journal:  Nat Rev Genet       Date:  2015-11-10       Impact factor: 53.242

3.  Variability in assigning pathogenicity to incidental findings: insights from LDLR sequence linked to the electronic health record in 1013 individuals.

Authors:  Maya S Safarova; Eric W Klee; Linnea M Baudhuin; Erin M Winkler; Michelle L Kluge; Suzette J Bielinski; Janet E Olson; Iftikhar J Kullo
Journal:  Eur J Hum Genet       Date:  2017-02-01       Impact factor: 4.246

4.  Rates of Actionable Genetic Findings in Individuals with Colorectal Cancer or Polyps Ascertained from a Community Medical Setting.

Authors:  Adam S Gordon; Elisabeth A Rosenthal; David S Carrell; Laura M Amendola; Michael O Dorschner; Aaron Scrol; Ian B Stanaway; Shannon DeVange; James D Ralston; Hana Zouk; Heidi L Rehm; Eric Larson; David R Crosslin; Kathy A Leppig; Gail P Jarvik
Journal:  Am J Hum Genet       Date:  2019-08-15       Impact factor: 11.025

5.  Next-generation sequencing of 100 candidate genes in young victims of suspected sudden cardiac death with structural abnormalities of the heart.

Authors:  C L Hertz; S L Christiansen; L Ferrero-Miliani; M Dahl; P E Weeke; G L Ottesen; R Frank-Hansen; H Bundgaard; N Morling
Journal:  Int J Legal Med       Date:  2015-09-17       Impact factor: 2.686

6.  SCN5A (NaV1.5) Variant Functional Perturbation and Clinical Presentation: Variants of a Certain Significance.

Authors:  Brett M Kroncke; Andrew M Glazer; Derek K Smith; Jeffrey D Blume; Dan M Roden
Journal:  Circ Genom Precis Med       Date:  2018-05

7.  Preconception Carrier Screening by Genome Sequencing: Results from the Clinical Laboratory.

Authors:  Sumit Punj; Yassmine Akkari; Jennifer Huang; Fei Yang; Allison Creason; Christine Pak; Amiee Potter; Michael O Dorschner; Deborah A Nickerson; Peggy D Robertson; Gail P Jarvik; Laura M Amendola; Jennifer Schleit; Dana Kostiner Simpson; Alan F Rope; Jacob Reiss; Tia Kauffman; Marian J Gilmore; Patricia Himes; Benjamin Wilfond; Katrina A B Goddard; C Sue Richards
Journal:  Am J Hum Genet       Date:  2018-05-10       Impact factor: 11.025

8.  Return of genomic results to research participants: the floor, the ceiling, and the choices in between.

Authors:  Gail P Jarvik; Laura M Amendola; Jonathan S Berg; Kyle Brothers; Ellen W Clayton; Wendy Chung; Barbara J Evans; James P Evans; Stephanie M Fullerton; Carlos J Gallego; Nanibaa' A Garrison; Stacy W Gray; Ingrid A Holm; Iftikhar J Kullo; Lisa Soleymani Lehmann; Cathy McCarty; Cynthia A Prows; Heidi L Rehm; Richard R Sharp; Joseph Salama; Saskia Sanderson; Sara L Van Driest; Marc S Williams; Susan M Wolf; Wendy A Wolf; Wylie Burke
Journal:  Am J Hum Genet       Date:  2014-05-08       Impact factor: 11.025

9.  Variable population prevalence estimates of germline TP53 variants: A gnomAD-based analysis.

Authors:  Kelvin C de Andrade; Megan N Frone; Talia Wegman-Ostrosky; Payal P Khincha; Jung Kim; Amina Amadou; Karina M Santiago; Fernanda P Fortes; Nathanaël Lemonnier; Lisa Mirabello; Douglas R Stewart; Pierre Hainaut; Luiz P Kowalski; Sharon A Savage; Maria I Achatz
Journal:  Hum Mutat       Date:  2018-11-19       Impact factor: 4.878

10.  Psychiatric genetics researchers' views on offering return of results to individual participants.

Authors:  Kristin M Kostick; Cody Brannan; Stacey Pereira; Gabriel Lázaro-Muñoz
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2018-10-25       Impact factor: 3.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.